Gerd Geisslinger

发表

The COVID-19 PHARMACOME: Rational Selection of Drug Repurposing Candidates from Multimodal Knowledge Harmonization

Martin Hofmann-Apitius, Andrea Zaliani, Reagon Karki, 2020, bioRxiv.

Pharmacological plasticity—How do you hit a moving target?

Gerd Geisslinger, Michael J. Parnham, M. Parnham, 2019, Pharmacology research & perspectives.

Machine-learned analysis of the association of next-generation sequencing–based human TRPV1 and TRPA1 genotypes with the sensitivity to heat stimuli and topically applied capsaicin

Jörn Lötsch, Michael C. Thrun, Gerd Geisslinger, 2018, Pain.

Drug Repurposing for the Development of Novel Analgesics.

Gerd Geisslinger, M. Parnham, G. Geisslinger, 2016, Trends in pharmacological sciences.

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis.

Gerd Geisslinger, Ewgenij Proschak, Daniel Merk, 2017, Journal of medicinal chemistry.

Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects.

Jörn Lötsch, Gerd Geisslinger, J. Lötsch, 2011, Drug discovery today.

Toponomics analysis of drug-induced changes in arachidonic acid-dependent signaling pathways during spinal nociceptive processing.

Gerd Geisslinger, Dieter Steinhilber, D. Steinhilber, 2009, Journal of proteome research.

Incidence and Costs of Adverse Drug Reactions During Hospitalisation

Kay Brune, Gerd Geisslinger, Manfred Criegee-Rieck, 2000, Drug safety.

Benefit-Risk Assessment of Rofecoxib in the Treatment of Osteoarthritis

Gerd Geisslinger, G. Geisslinger, Helmut Schmidt, 2004, Drug safety.

Specific Inhibition of IκB Kinase Reduces Hyperalgesia in Inflammatory and Neuropathic Pain Models in Rats

Gerd Geisslinger, Martin Michaelis, M. Michaelis, 2004, The Journal of Neuroscience.

Cyclooxygenase‐independent actions of cyclooxygenase inhibitors

Gerd Geisslinger, J. Pfeilschifter, G. Geisslinger, 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Genetic modulation of the pharmacological treatment of pain.

Jörn Lötsch, Gerd Geisslinger, J. Lötsch, 2009, Pharmacology & therapeutics.

[Generating knowledge from complex data sets in human experimental pain research].

Jörn Lötsch, Gerd Geisslinger, Carmen Walter, 2019, Schmerz.

GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence

Jörn Lötsch, David Goldman, Gerd Geisslinger, 2006, Nature Medicine.

Chain length-specific properties of ceramides.

Gerd Geisslinger, S. Grösch, G. Geisslinger, 2012, Progress in lipid research.

Pharmacokinetic modeling to predict morphine and morphine‐6‐glucuronide plasma concentrations in healthy young volunteers

Jörn Lötsch, Gerd Geisslinger, J. Lötsch, 2002, Clinical pharmacology and therapeutics.

Proteomics in Neuropathic Pain Research

Gerd Geisslinger, G. Geisslinger, E. Niederberger, 2008, Anesthesiology.

Common non-epigenetic drugs as epigenetic modulators.

Jörn Lötsch, Petra Schneider, Gisbert Schneider, 2013, Trends in molecular medicine.

Current evidence for a genetic modulation of the response to analgesics

Jörn Lötsch, Gerd Geisslinger, J. Lötsch, 2006, Pain.

Peripheral opioid analgesia in experimental human pain models.

Jörn Lötsch, Gerd Geisslinger, J. Lötsch, 2003, Brain : a journal of neurology.

Pattern of neuropathic pain induced by topical capsaicin application in healthy subjects

Jörn Lötsch, Alfred Ultsch, Gerd Geisslinger, 2015, Pain.

Functional genomics of pain in analgesic drug development and therapy.

Jörn Lötsch, Alfred Ultsch, Gerd Geisslinger, 2013, Pharmacology & therapeutics.

Ziconotide for treatment of severe chronic pain

Jörn Lötsch, Gerd Geisslinger, J. Lötsch, 2010, The Lancet.